What happened with MRK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Merck & Co.’s revenue comes from medicines that treat human diseases and vaccines that prevent them. It sells medicines to drug wholesalers, retailers, hospitals and government and managed-care buyers, rather than mainly to patients directly. Its business depends heavily on the cancer treatment Keytruda, its largest product. Vaccine brands include Gardasil and Gardasil 9; the U.S. government’s Vaccines for Children program buys a large part of its pediatric and adolescent vaccines.
Its smaller Animal Health business sells veterinary medicines, vaccines and health-management products and services for livestock and pets. Veterinarians, distributors, animal producers and pet owners are its buyers.
Merck’s earnings depend on patent protection and a continuing supply of successful new products and uses to replace sales lost as older products lose exclusivity. Insurers and governments negotiate prices and decide which medicines they cover, while U.S. laws require rebates and discounts for specified public programs and buyers. Merck must also obtain and maintain regulatory approval in each market before it can sell a product.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Merck’s results depend heavily on Keytruda, making Roche’s competing Tecentriq an important cancer-treatment comparison missing from this list.
Bristol Myers Squibb competes with Merck in cancer immunotherapy, but also receives a share of Merck’s Winrevair sales as royalties and pays Merck royalties on Reblozyl. Watch Reblozyl demand: its sales feed directly into Merck’s royalty revenue.
AstraZeneca is both a rival and a partner for Merck: its cancer medicine Imfinzi competes with Keytruda, while the companies share returns from Lynparza and collaborate on Koselugo. Lynparza sales are therefore relevant to Merck’s income as well as AstraZeneca’s.
Pfizer competes with Merck for sales of pneumococcal vaccines and COVID-19 medicines: its vaccines rival Vaxneuvance and Capvaxive, while Paxlovid competes with Lagevrio.
GSK competes with Merck for sales of preventive HPV vaccines, cancer immunotherapies and respiratory medicines. Its asthma and COPD inhaler business offers a comparison for Merck’s growing respiratory business, while its preventive HPV vaccines overlap with Merck’s vaccine business.
Sanofi and Merck compete in preventive vaccines, selling to publicly funded buyers among others, but jointly develop and distribute Vaxelis, a childhood vaccine covering six diseases. U.S. Vaxelis sales flow through their joint venture, so watch the partners’ share of its profits rather than their reported vaccine sales.
Johnson & Johnson competes with Merck in prescription medicines for pulmonary hypertension and cancer. Their former arrangement for Merck to market Remicade and Simponi has ended, so those products no longer provide the same business link.
Moderna shares an oncology trial stake with Merck through their jointly developed, individualized mRNA cancer therapy used with Keytruda. Results from that combination matter to both companies, unlike Moderna’s existing COVID-19 vaccine sales.
Regeneron competes with Merck in cancer immunotherapy through Libtayo, a rival to Keytruda. Libtayo news is the relevant comparison for Merck, rather than Regeneron’s EYLEA eye-medicine sales.
BeOne’s Tevimbra competes directly with Merck’s Keytruda in cancer immunotherapy, but BeOne’s largest drug business is Brukinsa. Watch Tevimbra specifically when assessing competition for Merck, rather than treating BeOne’s overall sales growth as a Keytruda signal.
Elanco competes with Merck Animal Health in products that protect pets from parasites, vaccines and livestock disease prevention. Its pet and farm-animal sales provide separate comparisons for Merck’s companion-animal and livestock businesses.
Gilead competes with Merck in HIV and COVID-19 medicines, but also jointly develops an HIV treatment combining islatravir and lenacapavir. News on that combination concerns a shared development project, not just competition for medicine sales.
Novartis competes with Merck for cancer-medicine sales, including treatments for advanced renal cell carcinoma alongside Merck’s Keytruda combinations and Welireg. Its everolimus-containing treatment is the concrete comparison to watch in that kidney-cancer market.
Novartis AG earningsNVS
Novartis's report can show demand for its everolimus-containing treatment in advanced kidney cancer, a market that also includes Merck's Keytruda combinations and Welireg.
Look for Novartis's demand disclosures on the everolimus-containing treatment; its total sales are not a signal for this kidney-cancer market. Steady or rising demand would show that Merck still faces a strong rival here. Weaker demand would suggest less pressure from this particular treatment, but would not prove that Merck gained sales.
GSK plc earningsGSK
If GSK reports on preventive HPV vaccine demand, its results will offer a read on the market shared with Merck's Gardasil business.
Focus on any HPV-vaccine demand GSK discloses, not its total vaccine sales, which include other products. Steady demand would show that the competitive market for Gardasil remains active. Weaker demand could ease pressure in that market, but cannot by itself establish a change in Merck's sales.
Merck & Co., Inc. earningsThis company
Merck's report will show whether Keytruda growth and other medicine sales can offset Gardasil's decline, or leave the business too dependent on one cancer drug.
Read Keytruda and Gardasil sales together. Continued growth in Keytruda with a smaller decline in Gardasil would show that Merck's main growth engine is still running and the vaccine gap is narrowing. Slower Keytruda sales alongside another Gardasil decline would show that its biggest product is not filling that gap and sales remain concentrated in a few products.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb's report can show demand for Reblozyl and Winrevair, two medicines tied to royalty income for Merck.
Watch Bristol Myers Squibb's disclosures on Reblozyl and Winrevair demand or sales, alongside any related royalty income Merck reports. Stronger demand with higher Merck income would show these partner revenue streams growing. Weaker demand, or sales growth that does not translate into higher Merck income, would show that the products are not providing the same support to Merck's revenue.
Gilead Sciences Inc earningsGILD
If Gilead updates the jointly developed HIV treatment in its report, readers can gauge the outlook for this shared research project with Merck.
Watch for any Gilead update on progress or setbacks for the combination of islatravir and lenacapavir. Progress would support the potential for Merck to share in a future HIV treatment opportunity; a setback would weaken that prospect. Neither outcome would mean Merck's current medicine sales have changed.
AstraZeneca PLC earningsAZN
AstraZeneca's report can show demand for Lynparza, whose profits Merck shares, making its sales relevant to their alliance income.
Compare AstraZeneca's Lynparza sales with the Lynparza alliance revenue Merck reports. Rising sales alongside higher Merck revenue would show a growing contribution from the shared product. Weaker sales, or sales growth without a corresponding increase in Merck's income, would show that costs and other factors matter; sales alone do not reveal Merck's profit share.
Sanofi earningsSNY
If Sanofi reports on Vaxelis, its results will offer a read on the joint-venture profits shared with Merck from this childhood vaccine.
Look for Vaxelis U.S. sales and the joint venture's profit, not the partners' total vaccine sales. Stronger Vaxelis sales and venture profits could mean a larger contribution to Merck; weaker figures could mean less. The key is the venture's profit, not total vaccine sales.
Pfizer Inc. earningsPFE
If Pfizer reports on pneumococcal-vaccine and COVID-19 medicine demand, its results can show the competition facing Merck's products in those markets.
Look separately at Pfizer's pneumococcal-vaccine and Paxlovid demand; Pfizer's total vaccine sales do not show the competition facing Merck's Vaxneuvance, Capvaxive or Lagevrio. Steady demand in those markets would show that Merck's products still face rivals. Weaker demand could ease that pressure, but would not prove Merck's sales rose.
BeOne Medicines Ltd. earningsONC
If BeOne reports on Tevimbra, its results can show demand for an immunotherapy that directly competes with Merck's Keytruda.
Look for BeOne's Tevimbra sales or demand, not its overall sales growth; Brukinsa is its largest drug business. Tevimbra growth would show stronger competition for Keytruda in the markets where they overlap. A Tevimbra slowdown could ease that pressure, but would not mean Keytruda sales must rise.
Elanco Animal Health Incorporated earningsELAN
Elanco's report can show demand for pet and livestock products that compete with Merck Animal Health.
Read Elanco's pet and livestock results separately; they correspond to Merck Animal Health's companion-animal and livestock businesses. Stronger demand in either category would show active competition for Merck in that market; weaker demand could ease pressure there. Do not treat a change in pet products as a signal for livestock, or vice versa.
Moderna, Inc. earningsMRNA
If Moderna updates its jointly developed individualized mRNA cancer therapy used with Keytruda, its report can show how that Merck partnership is progressing.
Watch for any Moderna update on development of the individualized mRNA therapy used with Keytruda. Progress would support the potential for Merck to extend Keytruda's treatment options through the partnership; a setback would weaken that opportunity. Neither outcome establishes a change in Keytruda's current demand or sales.
